Petct In Neuroendocrine Tumors Clinicians Guides To Radionuclide Hybrid Imaging 1st Ed 2016 Valentina Ambrosini Editor by Valentina Ambrosini (editor), Stefano Fanti (editor) 9783319292021, 9783319292038, 3319292021, 331929203X, 2016938547 instant download after payment.

Clear and concise clinical indications for PET/CT in the management of the oncology  patient are presented in this series of 15 separate Booklets.

 The impact on better staging, tailored management and specific treatment of the patient with cancer has been achieved with the advent of this multimodality imaging technology. Early and accurate diagnosis will always pay, and clear information can be gathered with PET/CT on treatment responses. Prognostic information is gathered and can forward guide additional therapeutic options.

 It is a fortunate coincidence that PET/CT was able to derive great benefit from  radionuclide-labelled probes, which deliver good and often excellent target to nontarget signals.

Whilst labelled glucose remains the cornerstone for the clinical benefit achieved, a number of recent probes are definitely adding benefit. PET/CT is hence an evolving technology,  extending its applications and indications. Significant advances in the instrumentation and data processing available have also contributed to this technology, which delivers high throughput and a wealth of data, with good patient tolerance and indeed patient and  public acceptance. As an example, the role of PET/CT in the evaluation of cardiac disease is also covered, with emphasis on labelled rubidium and labelled glucose studies.